Reneo Pharmaceuticals Receives Fast Track Designation From FDA For Mavodelpar In A Genotype Af Long-Chain Fatty Acid Oxidation Disorder
Reneo Pharmaceuticals Receives Fast Track Designation From FDA For Mavodelpar In A Genotype Af Long-Chain Fatty Acid Oxidation Disorder
Reneo Pharmicals因Mavodelpar在基因型Af長鏈脂肪酸氧化障礙中獲得美國食品藥品管理局的快速通道認證
Reneo Pharmaceuticals Receives Fast Track Designation From FDA For Mavodelpar In A Genotype Af Long-Chain Fatty Acid Oxidation Disorder
Reneo Pharmicals因Mavodelpar在基因型Af長鏈脂肪酸氧化障礙中獲得美國食品藥品管理局的快速通道認證